Edit this post
Shilpa Medicare (SHILPAMEDCA) is engaged in the manufacture of pharmaceuticals. It was incorporated as a private limited company in November 1987 and was converted into a public limited company in November 1993. The company produces high-quality active pharmaceutical ingredients (APIs) with a focus on oncology, nutritional supplements, herbal products, specialty chemical products, drug intermediates, and develops new products. It is the largest manufacturer of APIs in India and has already received a certificate of suitability from EDQM, France. The manufacturing unit and R&D facilities are located in the Raichur district of Karnataka with annual installed capacities of 100 MT bulk drugs and 135 MT intermediates. It has bought 20.45 acres of land near its existing plant to set up a dedicated global standard facility for oncology products. Commercial production is expected to commence by January 2008. In FY07, the company was recognized as a Star Export House by the Ministry of Commerce & Industry. It received several awards like the Karnataka State Award for Excellence in Exports and the safety award from GRISD-Bellary Chapter & Karnataka State Safety Organization. It signed a memorandum of understanding with LOBA Finchemie AG, Austria, to acquire 100% shares of LOBA, which provides specialty APIs, organic intermediates, biochemical diagnostics, and customs synthesis. Approvals from South Korea FDA (KFDA) officials for Gemcitabine HCL and Ambroxol HCL have opened up the South Korean markets for its products. Having filed EDMF for Gemcitabine HCL in 27 European countries, many reputed companies in Europe, India and US have started working with the company for Gemcitabine HCL. Products are exported to USA, Canada, Australia, Japan, Europe, South America, Africa, and Singapore, Taiwan, China and South Korea among other countries in Asia. The registered office is located at 10/80 1st Floor, Rajendra Gunj, Raichur-584102, Karnataka.
